

# Antifungal Drugs Market Growth Outlook : Projected to Hit \$ 25.0 Billion by 2030 at 3.9% CAGR

PORTLAND, KS, UNITED STATES, February 6, 2025 /EINPresswire.com/ -- Rise in incidences of fungal and nosocomial infections, surge in initiatives by public and private organizations to spread awareness about myriad of fungal infections, and growth in prevalence of fungal infections such as aspergillosis and candidiasis drive the growth of the [global antifungal drugs market](#). Furthermore, upsurge in number of drug approvals provide lucrative opportunities for the expansion of the global anti-fungal drugs market during the forecast period.



According to the report published by Allied Market Research, the global Antifungal Drugs Market generated \$16.6 billion in 2020, and is projected to reach \$25.0 billion by 2030, witnessing a CAGR of 3.9% from 2021 to 2030.

Request Sample Copy of the Report: <https://www.alliedmarketresearch.com/request-sample/2370>

Market Segmentation:-

By Drug Class:

- Azoles
- Polyenes
- Allylamines
- Echinocandins
- Others

By Infection Type:

Superficial Antifungal Infections

Systemic Antifungal Infections

By Therapeutic Indications:

Aspergillosis

Dermatophytosis

Candidiasis

Others

By Dosage Forms:

Oral

Topical

Others

By Region:

North America (U.S., Canada, Mexico)

Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe)

Asia-Pacific (Japan, China, Australia, India, South Korea, Rest of Asia-Pacific)

LAMEA (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)

Request for Customization –

<https://www.alliedmarketresearch.com/request-for-customization/2370>

Regional Growth Dynamics:

North America contributed to the highest share in terms of revenue in 2020, holding more than two-fifths of the total market share, and is estimated to continue its dominant share by 2030. However, Asia-Pacific is projected to manifest the fastest CAGR of 5.2% during the forecast period.

Competitive Landscape:

Pfizer Inc.

Novartis AG

Merck & Co., Inc.

Johnson & Johnson

Astellas Pharma Inc.

GlaxoSmithKline plc  
AbbVie Inc.  
Sanofi  
Bayer AG  
Mylan N.V.

Recent developments:

**Approval of New Antifungal Drugs:** In recent years, several new antifungal drugs have received regulatory approvals. For example, in 2021, the U.S. Food and Drug Administration (FDA) approved Brexafemme (ibrexafungerp) from SCYNEXIS, Inc. for the treatment of vulvovaginal candidiasis. This approval marked the first new oral antifungal drug class approved for this indication in over 20 years. Similarly, other drugs such as bafinetant and olorofim are in late-stage clinical development and show promise in addressing drug-resistant fungal infections.

**Increased Focus on Drug-Resistant Fungal Infections:** The rise in antifungal drug resistance has prompted increased research and development activities to address drug-resistant fungal infections. Pharmaceutical companies are investing in developing new antifungal agents, combination therapies, and alternative treatment options to combat resistant strains. Additionally, there is a growing emphasis on developing diagnostics to detect antifungal resistance more effectively.

Buy this Premium Research Report: <https://www.alliedmarketresearch.com/purchase-enquiry/2370>

VALUE PROPOSITIONS RELATED TO THE REPORT:

Powered with Complimentary Analyst Hours and Expert Interviews with Each Report  
Comprehensive quantitative and qualitative insights at segment and sub-segment level  
Covid 19 impact trends and perspective

Granular insights at global/regional/country level

Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment

Blanket coverage on competitive landscape

Winning imperatives

Exhaustive coverage on 'Strategic Developments' registered by leading players of the market

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and

achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa

Allied Market Research

+ + 1 800-792-5285

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

[YouTube](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/783556546>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.